Brought to you by 
S2, VeroScience license Cycloset to Santarus
18 Oct 2010
Executive Summary
VeroScience LLC (metabolic disease, cancer, and immune disorders) and specialty pharmaco partner S2 Therapeutics Inc. have licensed Santarus Inc. (drug candidates for gastrointestinal and metabolic disorders) exclusive rights to commercialize and manufacture the Type II diabetes drug Cycloset (bromocriptine mesylate) in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
S2, VeroScience license Cycloset to Santarus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice